High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer

1Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Background. Forkhead box (FOX) A1 is a potential therapeutic biomarker that has been investigated in various human cancers. Limited data exist about FOXA1 biologic role in epithelial ovarian cancer (EOC). Aim. This study assessed FOXA1 immunohistochemical (IHC) expression and evaluated its association with clinico-pathological parameters in EOC including overall and diseasefree survivals (OS, DFS) and patients outcome. Methods. Patients socio-epidemiologic, clinical, radiological, laboratory, surgical, and follow-up data were collected. After histopathologic typing, grading and staging, FOXA1 IHC expression was scored in 98 EOC specimens. Clinico-pathological associations were investigated in high-And low-FOXA1 expression groups using appropriate statistical methods. Kaplan?Meier method was used for survival analysis. Results. FOXA1 tumor cell nuclear staining was detected in 63.3% of EOC with weak, moderate and strong scores (28.6%, 12.2% and 22.5% respectively). Comparing highand low-expression groups (34.7% and 65.3% respectively), high FOXA1 was associated with larger tumors, low mean serum CA-125, tumor histopathology (mucinous and lowgrade serous), type I EOC, limited tumors anatomical extent, absence of nodal or distant metastases and omental nodules, earlier FIGO stages, non-recurrent tumors and survival advantage with longer and OS and DFS (all p ; 0.05). Independent predictors of high FOXA1 expression included: omental nodules, tumors anatomical extent and tumors size (p; 0.001, = 0.046 and = 0.023 respectively). Conclusion. FOXA1 is frequently expressed in EOC notably mucinous and low-grade serous carcinomas in association with favorable prognostic clinico-pathological parameters and longer OS and DFS. It likely has a suppressor function in EOC and could be recommended as a prognostic and therapeutic biomarker.

References Powered by Scopus

World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects

0
19958Citations
N/AReaders
Get full text

Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4

957Citations
N/AReaders
Get full text

The dualistic model of ovarian carcinogenesis revisited, revised, and expanded

753Citations
N/AReaders
Get full text

Cited by Powered by Scopus

FOXA1 expression and its association with mucin expression and KRAS mutation in ovarian mucinous tumors: implications for tumor progression and differentiation

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Sheta, H., Hafez, A. A. E., Saif, M., Elsergany, A. R., Emam, D. A., & Abdelrazik, M. M. (2021). High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer. Pathologica, 113(2), 102–114. https://doi.org/10.32074/1591-951X-217

Readers over time

‘22‘23‘2401234

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

100%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

67%

Agricultural and Biological Sciences 1

33%

Save time finding and organizing research with Mendeley

Sign up for free
0